Research programme: bacterial biofilm inhibitors - ProclaRx

Drug Profile

Research programme: bacterial biofilm inhibitors - ProclaRx

Alternative Names: PCL 1402; PCL-1404; PCL-1406; PCL-1407

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Nationwide Children's Hospital; Ohio State University; University of Southern California
  • Developer ProclaRx
  • Class Antibodies; Vaccines
  • Mechanism of Action Bacterial outer membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Infections; Otitis media; Sinusitis

Most Recent Events

  • 29 Aug 2016 ProclaRx plans IND-enabling studies for PCL 1407 in Infections in the fourth quarter of 2017 (ProclaRx pipeline, August 2016)
  • 29 Aug 2016 ProclaRx plans IND-enabling studies for PCL 1406 in Infections in the first quarter of 2017 (ProclaRx pipeline, August 2016)
  • 29 Aug 2016 ProclaRx plans IND-enabling studies for PCL 1404 in Sinusitis in the fourth quarter of 2016 (ProclaRx pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top